Escugen is a clinical-stage biotech company located in Shanghai, China, focusing on the R&D of innovative ADC drugs. ESG401, the most advanced development program of Escugen, is an innovative Trop-2 ADC which has entered Phase III clinical trials. Escugen’s new generation of ADC platform, EZWi-Fit® has significant competitive advantages in safety, efficacy, anti-drug-resistance, and pharmacokinetic features. Leveraging the EZWi-Fit® platform technology, Escugen is rapidly expanding its ADC pipelines targeting new or validated targets. Escugen has also successfully licensed the EZWi-Fit® platform technology to multiple domestic and international biotech companies, empowering their innovative ADC projects.
ESG401 entered Phase III clinical trials in China
ESG206 initiated FIH trail in China
EZWi-Fit® ADC technology platform patent submission
Completion of Round A+ fund-raising with nearly 100 million CNY
ESG401 was granted IND approval and initiated patient enrollment
ESG206 IND application was approved in China and Australia, respectively； ESG103 IND application was approved by CED and FDA, respectively
Establishment of an innovative ADC technology platform
Completion of Round A fund-raising with a total of 130 million CNY
Pre-IND application of the first pipeline ESG401
Completion of Round Pre-A fund-raising with 40 million CNY
The company was established in Zhangjiang, Shanghai, and the laboratory in Pharma Valley was operational
Acquired the Seed and Angle Funds with 35 million CNY
Veteran researcher in the field of R&D of antibody-based drugs, with more than 20 years of industry experience in the US and China; one of the contributors of the world's first fully human antibody drug development using transgenic mice
Previously served as the Project Leader of multiple antibody developments at Amgen/Abgenix, and as the Chief Scientific Officer at Genor Biopharma （Shanghai，China）
Led multiple Stated-funded National Key Program of Innovative Drug Development
Postdoc. in Molecular Biology and Biochemistry at the University of Southern California, Ph.D. in Pharmacology from Temple University School of Medicine
Over 15 years of experience in antibody drug manufacturing and development, with experience in filing over 30 innovative drug applications
Former Senior Scientist at Amgen, involved in multiple antibody development projects, and Head of Quality at Genor Biopharma
Member of the Expert Committee of the China Pharmaceutical Association, Visiting Professor and Ph.D. Advisor at University of Kansas
Postdoc. in Pharmaceutical Chemistry and Ph.D. in Biochemistry at University of Kansas
30 years of clinical experience, including 4 years as a physician and 15 years in clinical development
Served as the leader in over 30 clinical trials
Former executive at multiple inational and domestic pharmaceutical companies, biotechnology firms, and clinical CROs
Postdoc. at the University of Michigan, Ph.D. from Peking University Health Science Center
